-$0.58 EPS Expected for VERONA PHARMA P/S (VRNA) This Quarter
Equities analysts forecast that VERONA PHARMA P/S (NASDAQ:VRNA) will post ($0.58) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for VERONA PHARMA P/S’s earnings. The lowest EPS estimate is ($0.76) and the highest is ($0.38). VERONA PHARMA P/S reported earnings of ($1.61) per share in the same quarter last year, which suggests a positive year over year growth rate of 64%. The company is expected to issue its next quarterly earnings results on Tuesday, May 14th.
Zacks’ EPS calculations are a mean average based on a survey of research firms that follow VERONA PHARMA P/S.
VERONA PHARMA P/S (NASDAQ:VRNA) last released its quarterly earnings data on Tuesday, February 26th. The company reported ($0.28) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.43) by $0.15.
An institutional investor recently bought a new position in VERONA PHARMA P/S stock. Aisling Capital Management LP purchased a new position in shares of VERONA PHARMA P/S (NASDAQ:VRNA) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 443,596 shares of the company’s stock, valued at approximately $4,281,000. VERONA PHARMA P/S makes up about 4.5% of Aisling Capital Management LP’s holdings, making the stock its 9th largest holding. Aisling Capital Management LP owned 3.38% of VERONA PHARMA P/S as of its most recent filing with the Securities and Exchange Commission (SEC). 57.41% of the stock is currently owned by hedge funds and other institutional investors.
NASDAQ:VRNA opened at $6.42 on Friday. The firm has a market capitalization of $84.28 million, a PE ratio of -3.18 and a beta of -1.17. VERONA PHARMA P/S has a 1-year low of $5.52 and a 1-year high of $18.20.
VERONA PHARMA P/S Company Profile
Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and IIa clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease and cystic fibrosis.
Read More: How Investors Use a Balance Sheet
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for VERONA PHARMA P/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VERONA PHARMA P/S and related companies with MarketBeat.com's FREE daily email newsletter.